• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Opinion
Video

A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.

Video content above is prompted by the following questions:

  • Discuss the data that was presented at the ASCO 2024 on combination use amivantamab and lazertinib in the CHRYSALIS-2 study for patients who were treatment-naïve or had ≤ 2 prior lines.
  • Based on this study, how do you think amivantamab plus lazertinib compares with other current therapies used for EGFR mutations in NSCLC?
  • How might the safety data from this study impact treatment decisions and management strategies in clinical practice?
Related Videos
Ticiana Leal, MD
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Ana Baramidze, MD, PhD
Ticiana Leal, MD, Emory Winship Cancer Institute
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Jason Porter, MD, an expert on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Related Content
Martin Dietrich, MD, PhD

Research Priorities Evolve With Amivantamab's Broader NSCLC Indications

November 21st 2024
Article

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).

Read More

FDA | Image Credit: © Artur-stock.adobe.com

FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC

November 18th 2024
Article

The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).

Read More

Lung cancer | Image Credit: © Crystal light - stock.adobe.com

Tailored Management Needed for Male Patients With NSCLC After Surgery

November 15th 2024
Article

Lung cancer is the top cause of cancer-related death worldwide.

Read More

Lung cancer image | Image Credit: © appledesign-stock.adobe.com

Sunvozertinib NDA Submitted to FDA for NSCLC

November 8th 2024
Article

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer (NSCLC).

Read More

Biomarker Scrabble tiles | Image Credit: © lexiconimages-stock.adobe.com

Improving Early-Stage Lung Cancer Care

October 30th 2024
Article

More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery.

Read More

Martin Dietrich, MD, PhD

Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib

October 24th 2024
Article

Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.

Read More

© 2024 MJH Life Sciences
AJMC®
All rights reserved.